stockrowIndivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
Follow SUPN
Alert me
Indivior Pharmaceuticals Inc. (SUPN) EBITDA
Indivior Pharmaceuticals Inc.'s EBITDA for fiscal 2025 was $282.0M, up 327.3% from $66.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $571.0M. Over the past ten years it has ranged from −$143.0M (fiscal 2023) to $378.0M (fiscal 2015); the current reading is higher than 82% of that period. Indivior Pharmaceuticals Inc. ranks 10th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $282.0M | 327.27% |
| FY2024 | $66.0M | — |
| FY2023 | −$143.0M | — |
| FY2022 | −$64.0M | — |
| FY2021 | $235.0M | — |
| FY2020 | −$130.0M | — |
| FY2019 | $206.0M | (37.95%) |
| FY2018 | $332.0M | 61.17% |
| FY2017 | $206.0M | 26.38% |
| FY2016 | $163.0M | (56.88%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $183.0M | 12.96% |
| Jun 2026 | $162.0M | 14.89% |
| Mar 2026 | $141.0M | 65.88% |
| Dec 2025 | $85.0M | 73.47% |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $664.9M |
| SUPN Indivior Pharmaceuticals Inc. | $571.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $526.8M |
| LNTH Lantheus Holdings, Inc. compare | $386.4M |
| ALKS Alkermes plc compare | $217.3M |
| LQDA Liquidia Corporation compare | $170.3M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $132.4M |
| HIMS Hims & Hers Health, Inc. compare | −$62.2M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$165.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on SUPN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement